The lysozyme is suitable for lysing Micrococcus and E. coli, and delivers a five-fold increase in target protein recovery when compared with animal-derived lysozyme, the version commonly used in production. The increased efficiency offered by CellPrime recombinant human lysozyme, combined with high activity levels, could result in a reduction of overall production costs when compared with animal-derived lysozyme.
While proteins are typically expressed in E. coli at high levels, the extraction of functional protein is a critical step in the bioproduction process. Successful recovery is dependent on effective extraction methods such as disruption of bacterial cells by lysozyme or other enzymatic means.
“Use of animal-derived lysozyme for extracting protein therapeutics has significant drawbacks, including high lot-to-lot variation,” claims Janmeet Anant, global product manager for cell culture supplements. “In contrast, CellPrime recombinant human lysozyme is a more active cell lysis reagent, from non-animal origin, and is more consistent by virtue of being recombinant. As a result, it delivers increased protein yield while reducing regulatory concerns around animal-derived raw materials and risk of adventitious agents.”
